Javascript must be enabled to continue!
IoT Group Membership Management Using Decentralized Identifiers and Verifiable Credentials
View through CrossRef
Many IoT use cases can benefit from group communication, where a user requests an IoT resource and this request can be handled by multiple IoT devices, each of which may respond back to the user. IoT group communication involves one-to-many requests and many-to-one responses, and this creates security challenges. In this paper, we focus on the provenance that has been received by an authorized device. We provide an effective and flexible solution for securing IoT group communication using CoAP, where a CoAP client sends a request to a CoAP group and receives multiple responses by many IoT devices, acting as CoAP servers. We design a solution that allows CoAP servers to digitally sign their responses in a way that clients can verify that a response has been generated by an authorized member of the CoAP group. In order to achieve our goal, we leverage Decentralized Identifiers (DIDs) and Verifiable Credentials (VCs). In particular, we consider that each group is identified by a DID, and each group member has received a VC that allows it to participate in that group. The only information a client needs to know is the DID of the group, which is learned using DNSSEC. Our solution allows group members to rotate their signing keys, it achieves group member revocation, and it has minimal communication and computational overhead.
Title: IoT Group Membership Management Using Decentralized Identifiers and Verifiable Credentials
Description:
Many IoT use cases can benefit from group communication, where a user requests an IoT resource and this request can be handled by multiple IoT devices, each of which may respond back to the user.
IoT group communication involves one-to-many requests and many-to-one responses, and this creates security challenges.
In this paper, we focus on the provenance that has been received by an authorized device.
We provide an effective and flexible solution for securing IoT group communication using CoAP, where a CoAP client sends a request to a CoAP group and receives multiple responses by many IoT devices, acting as CoAP servers.
We design a solution that allows CoAP servers to digitally sign their responses in a way that clients can verify that a response has been generated by an authorized member of the CoAP group.
In order to achieve our goal, we leverage Decentralized Identifiers (DIDs) and Verifiable Credentials (VCs).
In particular, we consider that each group is identified by a DID, and each group member has received a VC that allows it to participate in that group.
The only information a client needs to know is the DID of the group, which is learned using DNSSEC.
Our solution allows group members to rotate their signing keys, it achieves group member revocation, and it has minimal communication and computational overhead.
Related Results
Efficacy of an Extended Half-Life GlycoPEGylated rFVIII (N8-GP): Pooled Analysis of ABR (Results from Two Clinical Trials)
Efficacy of an Extended Half-Life GlycoPEGylated rFVIII (N8-GP): Pooled Analysis of ABR (Results from Two Clinical Trials)
Abstract
Introduction
The short half-life of standard factor VIII (FVIII) products means that frequent injections (3 to 4 times/week) are needed for e...
Pelatihan Internet of Things (IoT) dalam peningkatan kompetensi siswa multimedia di SMK Perguruan Buddhi
Pelatihan Internet of Things (IoT) dalam peningkatan kompetensi siswa multimedia di SMK Perguruan Buddhi
Pelatihan Internet of Things (IoT) menjadi bagian penting dalam pengembangan kompetensi siswa jurusan multimedia di SMK Perguruan Buddhi. Era digital menuntut adanya pemahaman mend...
A Phase 1b, Dose-Finding Study Of Ruxolitinib Plus Panobinostat In Patients With Primary Myelofibrosis (PMF), Post–Polycythemia Vera MF (PPV-MF), Or Post–Essential Thrombocythemia MF (PET-MF): Identification Of The Recommended Phase 2 Dose
A Phase 1b, Dose-Finding Study Of Ruxolitinib Plus Panobinostat In Patients With Primary Myelofibrosis (PMF), Post–Polycythemia Vera MF (PPV-MF), Or Post–Essential Thrombocythemia MF (PET-MF): Identification Of The Recommended Phase 2 Dose
Abstract
Background
Myelofibrosis (MF) is a myeloproliferative neoplasm associated with progressive, debilitating symptoms that ...
Młodociani sprawcy przestępstw przeciwko mieniu
Młodociani sprawcy przestępstw przeciwko mieniu
The new Polish penal legislation of 1969 introduced special rules of criminal liability of young adult offenders' aged 17-20. In 1972 criminological research was undertaken in orde...
Dynamics of Mutations in Patients with ET Treated with Imetelstat
Dynamics of Mutations in Patients with ET Treated with Imetelstat
Abstract
Background: Imetelstat, a first in class specific telomerase inhibitor, induced hematologic responses in all patients (pts) with essential thrombocythemia (...
Risk of Infections with BCMA-Directed Immunotherapy in Multiple Myeloma
Risk of Infections with BCMA-Directed Immunotherapy in Multiple Myeloma
Abstract
Introduction: B cell maturation antigen (BCMA) is a novel target for T cell immunotherapy in MM including bispecific antibody (bsAb) and chimeric antigen re...
Combinatorial Antigen Targeting Strategy for Acute Myeloid Leukemia
Combinatorial Antigen Targeting Strategy for Acute Myeloid Leukemia
Introduction: Efforts to safely and effectively treat acute myeloid leukemia (AML) by targeting a single leukemia associated antigen with chimeric antigen receptor T (CAR T) cells ...
Efficacy and Safety of Subcutaneous Prophylaxis with Concizumab in Patients with Hemophilia a or B with Inhibitors: Results from explorer4, a Phase 2, Randomized, Open-Label, Controlled Trial
Efficacy and Safety of Subcutaneous Prophylaxis with Concizumab in Patients with Hemophilia a or B with Inhibitors: Results from explorer4, a Phase 2, Randomized, Open-Label, Controlled Trial
Introduction Concizumab is an anti-tissue factor pathway inhibitor (TFPI) monoclonal antibody in clinical development for the subcutaneous prophylactic treatment of hemophilia pati...

